# Epitalon Reviews — Independent summaries of the AEDG tetrapeptide research literature > An editorial review of twenty-five years of Epitalon (AEDG tetrapeptide) research: telomerase activation, pineal melatonin regulation, lifespan studies in rodents and primates, and the state of independent replication. ## The short version Epitalon (also written Epithalon) is a four-amino-acid research peptide — the sequence Ala-Glu-Asp-Gly, or *AEDG* for short — derived from a pineal-gland extract called epithalamin. It is not approved for human use anywhere in the major Western regulatory systems. What the published literature documents is this: in cell culture, the peptide has been shown to switch on *telomerase* (the enzyme that rebuilds the caps on the ends of chromosomes), extend those caps in normal human cells, and stimulate the pineal enzyme pathway that produces melatonin. Those findings come overwhelmingly from one Russian research laboratory over twenty-five years; independent Western replication appeared only in 2024–2025, and no randomized human trial has been published. People in research-use communities report effects — mostly around sleep and a general sense of vitality — that are anecdotal and unverified. For the community-reported picture alongside the published safety cautions, see [the effects page](/effects). ## What is Epitalon? Epitalon — registered also as Epithalon or Epithalone, and formally designated Alanyl-Glutamyl-Aspartyl-Glycine (AEDG) — is a synthetic tetrapeptide of molecular weight 390.35 Da, comprising four amino acids in the sequence Ala-Glu-Asp-Gly. It was developed by Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of Epithalamin, a polypeptide extract of bovine pineal gland. In 2017, LC-MS/MS analysis confirmed the AEDG sequence is present endogenously in the human pineal gland, providing a basis for the hypothesis that Epitalon is a bioactive fragment of a naturally occurring peptide rather than a wholly synthetic compound. The pineal gland occupies a particular position in aging biology: its output of melatonin declines progressively from the second decade of life onward, a change that correlates with a broad range of age-associated physiological shifts. Epithalamin — the natural extract from which Epitalon's sequence was isolated — had been studied since the 1970s for effects on reproductive aging, circadian rhythm, and tumor suppression in animal models. When Khavinson's group identified the AEDG tetrapeptide as the probable active fragment, they synthesized it and began a systematic program of in vitro, in vivo, and limited clinical research that now spans more than twenty-five years. The compound does not appear in any pharmacopeia. It is not approved by the FDA, the European Medicines Agency, or any other major regulatory body for human therapeutic use. Published human data consists of two small clinical series, both conducted by the same research group [12, 15]. The NIA Interventions Testing Program — the gold standard for independent evaluation of longevity claims in rodent models — has not evaluated Epitalon. ## What does the published research document? Three clusters of findings dominate the Epitalon literature. **Telomerase activation and telomere extension.** In telomerase-negative human fetal fibroblasts, Epitalon induced expression of the telomerase catalytic subunit hTERT and produced measurable telomere elongation [1]. A 2025 study from an independent British-Australian group extended this finding to cancer and normal human cell lines: in breast cancer lines (21NT, BT474), Epitalon (0.2–1 µg/ml) extended telomeres primarily via alternative lengthening of telomeres (ALT) activation — a 10-fold increase in 21NT cells; in normal fibroblasts and epithelial cells, extension occurred through hTERT upregulation and a 4- to 26-fold increase in telomerase activity [2]. This 2025 study is significant because it represents the first independent (non-Russian) in vitro confirmation of Epitalon's telomere-extension capacity. **Lifespan extension and tumor suppression in rodents.** In female Swiss-derived SHR mice, Epitalon administered subcutaneously at 1 µg/mouse for 5 consecutive days per month extended the mean lifespan of the last 10% of survivors by 13.3% and maximum lifespan by 12.3%, reduced bone marrow chromosomal aberrations by 17.1%, and inhibited leukemia development 6.0-fold compared with untreated controls [3]. In transgenic FVB/N HER-2/neu mice, similar treatment extended average and maximum lifespan by 13.5% and 13.9% respectively, decreased breast adenocarcinoma incidence 1.6-fold, increased tumor-free animals 3.7-fold, and suppressed HER-2/neu oncogene expression [4]. In Drosophila melanogaster, dietary Epitalon at concentrations as low as 0.001×10⁻⁶ wt.% extended lifespan 11–16%, an effect achieved at 16,000-fold lower concentration than melatonin producing comparable results [5]. **Pineal and circadian regulation.** Epitalon modulates melatonin synthesis directly in rat pinealocytes via the AANAT enzyme and pCREB transcription factor, restoring serotonin/gastrin/somatostatin-producing cell ratios in pinealectomized animals [17]. In senescent rhesus macaques (ages 20–26 years), intramuscular Epitalon at 10 µg/kg over 10 days restored evening melatonin synthesis and normalized the cortisol circadian pattern [11]. In a human clinical series of 75 women with pineal aging features, sublingual Epitalon at 0.5 mg/day for 20 days produced a 1.6-fold increase in melatonin excretion and statistically significant normalization of Clock, Cry2, and Csnk1e circadian gene expression [15]. ## The single-source caveat Nearly all of the published Epitalon literature originates from one institution: the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson. This concentration of evidence in a single research group is the defining limitation of the Epitalon record. Findings that have not been independently replicated — however internally consistent — carry a different epistemic weight than a body of evidence distributed across multiple laboratories and countries. The 2025 Al-dulaimi et al. study [2] represents a meaningful exception: it was conducted by researchers affiliated with institutions in the United Kingdom and Australia, using commercially sourced Epitalon, and it directly confirmed telomere extension in human cell lines through a mechanism consistent with the Khavinson group's earlier reports. A 2025 comprehensive review [13] also identified Epitalon's presence in the human pineal gland and catalogued the mechanistic evidence across ten proposed pathways — while explicitly noting the outstanding gaps: no comprehensive toxicology data, no stereoisomer studies, unresolved oral bioavailability, and the continued absence of multicenter replication. This site presents the research as it stands: a substantial preclinical and limited clinical record built by a single program, with promising recent independent confirmation in telomere biology and retinal biology, but without the multicenter RCT evidence that would ordinarily be required before any clinical conclusion could be drawn. ## What this site is Epitalon Reviews is an independent editorial project that indexes and summarizes the peer-reviewed literature on the AEDG tetrapeptide. Every claim on this site is sourced to a publication; every quantitative value cites the study that measured it. The pages that follow cover mechanism in depth [/research], the doses and routes used in published studies framed as research context [/dosage], ten questions from readers answered directly [/faq], the complete reference list with DOIs and PubMed links [/references], and the editorial methodology behind this project [/about]. --- An editorial digest of peer-reviewed literature on the AEDG tetrapeptide — not a clinic, not a vendor, not a source of medical advice.